Uric acid and oxidative stress—relationship with cardiovascular, metabolic, and renal impairment

ME Gherghina, I Peride, M Tiglis, TP Neagu… - International Journal of …, 2022 - mdpi.com
Background: The connection between uric acid (UA) and renal impairment is well known
due to the urate capacity to precipitate within the tubules or extra-renal system. Emerging …

Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease

C Borghi, E Agabiti-Rosei, RJ Johnson… - European journal of …, 2020 - Elsevier
During the last century, there has been an increasing prevalence of hyperuricaemia noted in
many populations. While uric acid is usually discussed in the context of gout …

[HTML][HTML] Uric acid and chronic kidney disease: still more to do

RJ Johnson, LGS Lozada, MA Lanaspa, F Piani… - Kidney International …, 2023 - Elsevier
Gout and hyperuricemia are present in 25% and 60% of patients with chronic kidney
disease (CKD), respectively. Despite the common association, the role of uric acid in the …

Management of hyperuricemia in patients with chronic kidney disease: a focus on renal protection

JT Kielstein, R Pontremoli, M Burnier - Current Hypertension Reports, 2020 - Springer
Abstract Purpose of Review In chronic kidney disease (CKD), plasma uric acid levels are
increased because of the decrease in glomerular filtration rate. However, in addition to CKD …

[HTML][HTML] Clinical effects of xanthine oxidase inhibitors in hyperuricemic patients

AFG Cicero, F Fogacci, RI Cincione, G Tocci… - Medical principles and …, 2021 - karger.com
This review aims to critically present the available clinical evidence supporting the treatment
of chronic hyperuricemia with xanthine oxidase inhibitors. For this reason, the studies …

Pathway from acute kidney injury to chronic kidney disease: molecules involved in renal fibrosis

A Niculae, ME Gherghina, I Peride, M Tiglis… - International Journal of …, 2023 - mdpi.com
Acute kidney injury (AKI) is one of the main conditions responsible for chronic kidney
disease (CKD), including end-stage renal disease (ESRD) as a long-term complication …

Hyperuricemia and progression of chronic kidney disease: a review from physiology and pathogenesis to the role of urate-lowering therapy

TH Lee, JJ Chen, CY Wu, CW Yang, HY Yang - Diagnostics, 2021 - mdpi.com
The relationship between hyperuricemia, gout, and renal disease has been investigated for
several years. From the beginning, kidney disease has been considered a complication of …

Review of urate-lowering therapeutics: from the past to the future

C Jenkins, JH Hwang, JB Kopp, CA Winkler… - Frontiers in …, 2022 - frontiersin.org
We reviewed all currently available ULT, as well as any medications in development using
following databases: United States Food and Drug Administration (FDA), European …

Febuxostat solubilization and stabilization approach using solid dispersion method: Synergistic effect of dicalcium phosphate dehydrate and chitosan

JS Sohn, JS Choi - International Journal of Biological Macromolecules, 2023 - Elsevier
Drug solubilization studies are continuously being conducted. Febuxostat (FBX) has a low
solubility in water. This study aims to develop a stable FBX-solid dispersion (SD) formulation …

Mechanistic insights into hyperuricemia-associated renal abnormalities with special emphasis on epithelial-to-mesenchymal transition: pathologic implications and …

P Balakumar, A Alqahtani, NA Khan… - Pharmacological …, 2020 - Elsevier
Though the pathogenesis of hyperuricemia-induced renal complications is not precisely
known, hyperuricemia has been recognized as an independent risk factor for renal disease …